Moderna, Inc. (MRNA) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Moderna, Inc. (Stock Symbol: MRNA) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry. The organization employs approximately 4986 professionals worldwide . The company has established itself as a major market leader with significant institutional backing.
Financial Performance & Key Metrics Analysis
Annual Revenue: $3078 million generating a -46.8% net profit margin .
Market Capitalization: $10550 million - Classified as a large-cap stock with institutional-grade stability.
Return on Equity (ROE): 140.0% - Exceptional shareholder return efficiency, indicating strong management effectiveness.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Moderna, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Moderna, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, positioning itself as a dominant large-cap market leader with significant competitive moats and institutional investor confidence . The company demonstrates robust operational efficiency through strong free cash flow generation of $13031 million annually . The company maintains a healthy -0.5% gross margin, indicating strong pricing power and operational efficiency.